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Thein vitro study of the combined effects of humoral antibody and lympho- 
cytes has been essential  in  attempting  to understand  the paradoxical  effect of 
humoral antibodies leading to the phenomenon of enhancement (1). Part of the 
mechanism has been considered to be the shielding  of cellular antigenic  deter- 
minants by humoral antibody from the lymphocytes. This could mask antigenic 
sites  preventing  recognition  and  result  in  an  afferent block and  also interfere 
with  the  cytotoxic effect  of  specifically  sensitized  lymphocytes  producing  an 
efferent block. Support for both these hypotheses has been demonstrated  (2-7). 
The blocking effect of humoral antibodies has been proposed to be of importance 
in the phenomena of tolerance, chimerism,  and the protection of the fetus from 
maternal  lymphocytes  (8).  However,  it  has  been  well  documented  in  certain 
systems that humoral  antibody and lymphocytes may act in concert to effect 
target  cells' destruction  (9,  10).  Under  different  experimental  conditions,  pre- 
treatment  of target  cells  with  humoral  antibody may protect  them  from the 
cytotoxic effect of immune lymphocytes or mediate their destruction  by a  nor- 
mal  lymphocyte population.  In  vivo  probably  a  balance  between  these  two 
phenomena occurs. 
In  experiments  concerning  the  combined  effects  of  sera  and  lymphocytes 
from Moloney sarcoma virus (MSV)l-infected rats vs.  MSV-transformed  target 
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cells,  we  found  that  lymphocyte-mediated  cytotoxicity was  influenced  in  two 
opposite  directions depending  on the serum concentration used to pretreat  the 
target  cells. With  some sera relative increased killing of target cells  was  found 
at higher serum concentrations which subsided upon dilution and  was  replaced 
by better cell survival at  lower concentrations. 
Materials and Methods 
Sourc6 of Lymphocytes and Sera.--Nine 5-day old Fischer rats were inoculated intramus- 
cularly with 0.1  ml of MSV prepared by the Moloney method  (11, 12).  Only two of these 
animals developed tumors, one of which regressed after 30 days. The other had a progressively 
growing tumor at the 49th  day when it was sacrificed.  Lymphocytes were harvested from 
axillary and  inguinal nodes from two rats without tumor 77  and  120 days after injection. 
Sera were collected from each rat 49, 77, and 106 days after injection with MSV. 
Cytotoxic Assay.---The cytotoxic effects were assayed on A78 target cells (Wistar rat MSV- 
transformed fibroblast line)  using the microcytotoxicity method of Takasugi and Klein (13) 
adapted to the study of serum as well as cell-medlated cytotoxicity. 50-100 target cells seeded 
in  the wells of microplates  (No.  3034,  Falcon Plastics,  Div. B-D Laboratories,  Inc.,  Los 
Angeles, Calif.) incubated 24 hr at 37°C with 5% CO~ were exposed to lymphocytes, sera, or 
both using six replicate wells for each serum dilution or lymphocyte concentration.  Guinea 
pig complement (1:10) was added for assessment of serum cytotoxicity. When lymphocytes 
and sera were tested together, the target cells were incubated with serial serum dilutions for 
45 rain, then washed, and the lymphocytes were added. Medium for cultivation, washing, and 
dilutions  was  Eagle's  minimal  essential  medium  with  10%  heat-inactlvated  fetal  bovine 
serum, 50 units/ml of penicillin, and 50 #g/ml of streptomycin. Mter 48 hr incubation,  the 
plates were washed with balanced salt solution, fixed with methanol, and stained by Giemsa 
and eosin methylene blue. The number of cells remaining in each well were counted. 
Sera.--All  immune sera were cytotoxic but their strength  differed considerably varying 
between 30 and 900-/o target cell reduction at a dilution of 1 : 10 with titers between 1 : 40 and 
1:320. The serum collected from the tumor-bearing rat was weak (30c7o target cell reduction 
and 1:40 titer). By indirect immunofluorescence the presence of antibodies was demonstrated. 
In a  1:20 dilution the different immune sera stained 40-70% of the A78 cells while the con- 
trol sera were negative. 
Lymphocytes.--Cytotoxicity  varied according to the ratio of lymphocytes to target cells. 
Since a  50:1  ratio was noncytotoxic with normal lymphocytes,  this ratio was used  in the 
experiments concerning the effect of antibodies. The specific cytotoxicity was low which can 
be explained by the long period elapsing after MSV infection (14). 
RESULTS 
Fig.  1 shows the combined effects of sera and the immune lymphocyte  popu- 
lation  (harvested  77  days  after  MSV  infection).  The  results  are  expressed  as 
the percentage of target cells in control wells to which the same ratio of normal 
lymphocytes  alone were added.  The mean number  of target cells without  lym- 
phocytes was  177.2  4-  71.2/well. 
Immune  lymphocytes  alone caused  a  33.5 %  reduction in target cell number 
compared  to  normal  lymphocytes.  Pretreatment  with  high  serum  concentra- 
tions  resulted  in  an  increased  destruction  of target  cells by three  of  the  sera. 
At lower concentrations,  one serum was without  effect, but the other three re- SKLIRZAK, KLEIN, YOSHIDA, AND  LAMON  999 
duced  target  cell  destruction,  and  as the  sera were further  diluted  this  effect 
disappeared or diminished. The control serum did not influence the cytotoxicity. 
Pretreatment with the immune sera alone, without addition of complement was 
not cytotoxic.  In the wells treated with serum from an animal with  a progres- 
sively  growing  tumor,  the  relative  target  cell  survival  was higher  though  the 
shape of the titration curve was similar  to the  others. This  might  be the  result 
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FIG.  1.  Influence of individual sera collected 49 and 77 days after MSV infection on the 
cytotoxic effect of lymphocytes.  The lymphocytes  were tested  77  days after infection  and 
caused 33.5% target cell reduction as indicated by the horizontal line. 
of several interacting factors. A  growth-stimulating  effect and a concentration- 
dependent  assistance  in cytotoxicity or blocking would explain the curve. 
Fig.  2  shows a  similar experiment  in which the sensitized lymphocytes were 
only slightly  cytotoxic  (12.9%  target  cell  reduction).  The  lymph  nodes  were 
harvested 106 days after MSV infection. Two immune sera were highly effective 
in assisting lymphocyte-mediated  cytotoxicity. None of these animals had pro- 
gressively growing tumors.  With  one serum,  the  above discussed high  relative 
target cell survival suggesting stimulation was obtained. 1000  INFLIYENCE  OF  ANTIBODIES  ON  LYMPHOCYTE  CYTOTOXICITY 
DISCUSSION 
These data suggest that  a synergistic  cytotoxic  effect  of  antiserum  and  lym- 
phocyte population  from a  sensitized host can take place when high  concentra- 
tions of antisera are used to coat the target cells. The same serum used in lower 
~:oncentrations  may  block  lymphocyte-mediated  cytotoxicity.  The  extent  of 
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FIG.  2.  Influence  of individual  sera collected  106 days after MSV infection  on the cyto- 
toxic effect of lymphocytes. The lymphocytes were tested 120 days after infection and caused 
ez  a 12.9 7o target cell reduction as indicated by the horizontal line. 
these  effects  obtained  with  individual  sera  varied.  The  phenomenon  of  anti- 
serum-treated  target  cell destruction by lymphocytes can thus be extended  to 
virally  determined  cell surface  antigen(s). 
Another  fact  which  is  suggested  by  these  data  is  that  the  sera  of  animals 
without progressive neoplasms may also inhibit the cytotoxic effect of  immune 
lymphocytes  at some dilutions  as effectively  as the  serum from a  "progressor" 
animal. A  similar blocking effect was obtained  by Ankerst  (15)  with  sera from 
tumor-free mice immunized by repeated injections  of small cell numbers in the 
adenovirus  12  system.  The  blocking  effect  was  found  to  be  in  the  7S  fraction SKURZAK,  KLEIN,  YOSHIDA,  AND  LAMON  1001 
The 19S fraction was cytotoxic in the presence of complement but did not block 
lymphocyte cytotoxicity. 
It seems that the classification of different individual antisera in  view  of the 
effect on lymphocyte-mediated cytotoxicity needs to be  correlated  to the  con- 
centrations used. 
It may be recalled  in  this  context  that  the  enhancement  phenomenon  was 
found to depend considerably on several factors, including the timing of immu- 
nization and the antigen dose as well as the cell type used for graft (16,  17). In 
experiments producing enhancement by passive antibody, the effect was highly 
dependent  on  the  antibody  dose  administered  (1).  Moreover,  in  experiments 
with  in  vivo  passive  transfer,  the  synergistic  effect  of  immune  serum  and  a 
lymphocyte population from sensitized mice was demonstrated  (16, 18). 
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